PSC
ELVN icon

Patient Square Capital’s Enliven Therapeutics ELVN Stock Holding History

Patient Square Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
212,500
+12,500
+6% +$531K 1.67% 15
2026
Q1 		$7.84M Sell
200,000
-108,141
-35% -$3M 1.39% 21
2025
Q4 		$4.75M Buy
308,141
+57,303
+23% +$1.14M 1.02% 23
2025
Q3 		$5.13M Buy
250,838
+5,000
+2% +$101K 1.37% 13
2025
Q2 		$4.93M Sell
245,838
-8,000
-3% -$151K 1.78% 11
2025
Q1 		$5M Buy
253,838
+29,800
+13% +$641K 2.07% 9
2024
Q4 		$5.04M Buy
224,038
+133,466
+147% +$3.46M 1.89% 8
2024
Q3 		$2.31M Buy
+90,572
New +$2.1M 0.86% 9

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Patient Square Capital's ELVN Position: Q2 2026 in Review

Patient Square Capital increased its Enliven Therapeutics (ELVN) stake by 6.3% in Q2 2026, buying an estimated $531K and bringing the position to 212,500 shares worth $10.8M. The position accounts for 1.67% of the portfolio, ranked #15.

Patient Square Capital first reported a position in ELVN in Q3 2024 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Patient Square Capital held 212,500 shares of Enliven Therapeutics worth $10.8M as of Q2 2026.
  • Patient Square Capital bought 12,500 Enliven Therapeutics shares in Q2 2026, an estimated $531K.
  • Enliven Therapeutics made up 1.67% of Patient Square Capital's portfolio in Q2 2026, its #15 holding.
  • Patient Square Capital first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.